Patients in the SANOVO China Phase III study were enrolled in the combination therapy of Vistusertib and Temsirolimus for first-line treatment of specific lung cancer patients with HuMab(00013) completed.

Zhixin Finance APP News, Hutchison China MediTech (00013) announced that the SANOVO China Phase III study on the combination therapy of Orpathys (savolitinib) and Tagrisso (osimertinib) for first-line treatment of specific non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations and MET overexpression has completed patient enrollment. The last patient for this study was enrolled on August 18, 2025.